Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
We found one of the target antigens of anti-carbamylated protein (CarP) antibody is carbamylated albumin (CarALB). Sensitivities of anti-CarALB antibody for anti-CCP antibody-positive rheumatoid arthritis (RA) and anti-CCP-negative RA are 44.6% and 18.3%, respectively (3.6% for healthy donors). Both Anti-CarP and anti-CarALB antibodies were positive in ~10-30% of other rheumatic diseases or collagen vascular diseases. We measured serum concentration of myeloperoxidase (MPO), which is the key enzyme of carbamylation in vivo, and found that MPO was higher in anti-CarALB-positive RA patients than in anti-CarALB-negative patients.
|